Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of adapted-dose cisplatin, 5-fluorouracil and docetaxel in locally advanced squamous cell carcinoma
2020-000770-21Phase 2Active
- Sponsor
- GORTEC
- Start
- Mar 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cisplatin, docetaxel and fluorouracil in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by GORTEC. Started Mar 2020; status: active.
02
Drugs
cisplatindocetaxelfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2020-000770-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000770-21.